| 4.135 -0.265 (-6.02%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.43 | 1-year : | 6.34 |
| Resists | First : | 4.65 | Second : | 5.43 |
| Pivot price | 3.86 |
|||
| Supports | First : | 3.78 | Second : | 3.25 |
| MAs | MA(5) : | 4.02 |
MA(20) : | 3.78 |
| MA(100) : | 3.51 |
MA(250) : | 7.73 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 64.8 |
D(3) : | 59 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 22.89 | Low : | 2.64 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CLGN ] has closed below upper band by 20.3%. Bollinger Bands are 5.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.6 - 4.63 | 4.63 - 4.64 |
| Low: | 4.05 - 4.08 | 4.08 - 4.1 |
| Close: | 4.09 - 4.14 | 4.14 - 4.16 |
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.
Sun, 01 Nov 2026
CollPlant Biotechnologies Ltd. (CLGN) Seasonal returns chart - Yahoo Finance UK
Fri, 30 Oct 2026
CollPlant Biotechnologies Ltd. (CLGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Thu, 29 Oct 2026
CollPlant Biotechnologies Ltd. (CLGN) stock price, news, quote and history - Yahoo Finance UK
Thu, 29 Oct 2026
A paid laser-computing deal gives CollPlant (CLGN) subsidiary a 12-month initial order. - Stock Titan
Tue, 27 Oct 2026
A 10% stockholder proposes selling 15,550 CollPlant (CLGN) shares. - Stock Titan
Mon, 26 Oct 2026
CollPlant Biotechnologies Ltd. Estimates – NASDAQ:CLGN - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 864520 (%) |
| Held by Institutions | 33.9 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.156e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 437.9 % |
| Return on Equity (ttm) | -63 % |
| Qtrly Rev. Growth | 318000 % |
| Gross Profit (p.s.) | -52.24 |
| Sales Per Share | -213.14 |
| EBITDA (p.s.) | -1.34211e+006 |
| Qtrly Earnings Growth | -9.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 1.54 |
| Dividend | 0 |
| Forward Dividend | 42220 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|